Inter-society consensus for the management of respiratory infections: acute bronchitis and chronic obstructive pulmonary disease

• Published in: Medicina Vol. 73; no. 2; pp. 163 - 173
• Main Authors: Lopardo, Gustavo, Pensotti, Claudia, Scapellato, Pablo, Caberlotto, Oscar, Calmaggi, Aníbal, Clara, Liliana, Klein, Manuel, Levy Hara, Gabriel, López Furst, María J, Mykietiuk, Analía, Pryluka, Daniel, Rial, María J, Vujacich, Claudia, Yahni, Diego
• Format: Journal Article Conference Proceeding
• Language: Spanish
• Published: Argentina 2013
• Subjects: Acute Disease; Anti-Bacterial Agents - therapeutic use; Argentina; Bronchitis - diagnosis; Bronchitis - drug therapy; Bronchitis - microbiology; Dyspnea - complications; Evidence-Based Medicine; Humans; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - drug therapy; Pulmonary Disease, Chronic Obstructive - microbiology; Risk Factors; Societies, Medical; Sputum - microbiology; Argentina; acute bronchitis; management of respiratory infections; COPD reactivation
• ISSN: 0025-7680

The Argentine Society for Infectious Diseases and other national societies issued updated practical guidelines for the management of acute bronchitis (AB) and reactivations of chronic obstructive pulmonary disease (COPD) with the aim of promoting rational use of diagnostic and therapeutic resources. AB is a condition characterized by inflammation of the bronchial airways which affects adults and children without underlying pulmonary disease. It is usually caused by a virus. The diagnosis is based on clinical findings after community acquired pneumonia has been ruled out. Treatment of AB is mainly symptomatic. Antibiotics should be used in immune-compromised hosts, patients with chronic respiratory or cardiac diseases and in the elderly with co-morbidities. Reactivation of COPD is defined as an acute change in the patient's baseline clinical situation beyond normal day to day variations, with an increase in dyspnea, sputum production and/or sputum purulence, warranting a change in medication. An increase in one symptom is considered a mild exacerbation, two as moderate, and the presence of three symptoms is considered a severe exacerbation. An infectious agent can be isolated in sputum in 50 to 75% of COPD reactivations. Moderate and severe episodes must be treated with antibiotics, amoxicillin/ beta-lactamase inhibitor, macrolides and fluoroquinolones are first choice drugs.